HK1095762A1 - Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy - Google Patents

Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy

Info

Publication number
HK1095762A1
HK1095762A1 HK07103389A HK07103389A HK1095762A1 HK 1095762 A1 HK1095762 A1 HK 1095762A1 HK 07103389 A HK07103389 A HK 07103389A HK 07103389 A HK07103389 A HK 07103389A HK 1095762 A1 HK1095762 A1 HK 1095762A1
Authority
HK
Hong Kong
Prior art keywords
diabetic nephropathy
microalbuminuriain
ctgf
therapy
patients
Prior art date
Application number
HK07103389A
Other languages
English (en)
Inventor
Flyvbjerg Allan
Guo Guangjie
David Y Liu
Thomas B Neff
Noelynn A Oliver
William R Usinger
Wang Qingjian
Original Assignee
Fibrogen Ing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Ing filed Critical Fibrogen Ing
Publication of HK1095762A1 publication Critical patent/HK1095762A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
HK07103389A 2004-02-11 2007-03-29 Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy HK1095762A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54412104P 2004-02-11 2004-02-11
US56101804P 2004-04-08 2004-04-08
US57840104P 2004-06-09 2004-06-09
US62080204P 2004-10-20 2004-10-20
PCT/US2005/004367 WO2005077413A1 (en) 2004-02-11 2005-02-11 Ctgf as target for the therapy of diabetic nephropathy

Publications (1)

Publication Number Publication Date
HK1095762A1 true HK1095762A1 (en) 2007-05-18

Family

ID=34865408

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07103389A HK1095762A1 (en) 2004-02-11 2007-03-29 Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy

Country Status (15)

Country Link
US (2) US20050214294A1 (xx)
EP (2) EP1715890B1 (xx)
CN (1) CN101884789A (xx)
AT (1) ATE400297T1 (xx)
AU (1) AU2005212371B2 (xx)
CA (1) CA2555789A1 (xx)
DE (1) DE602005008013D1 (xx)
DK (1) DK1715890T3 (xx)
ES (1) ES2311973T3 (xx)
HK (1) HK1095762A1 (xx)
IL (1) IL177437A (xx)
NZ (1) NZ549784A (xx)
PL (1) PL1715890T3 (xx)
PT (1) PT1715890E (xx)
WO (1) WO2005077413A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326361A (zh) * 1998-09-08 2001-12-12 亨利福特保健***公司 通过修饰、调节及抑制***生长因子来检查、预防和治疗肾脏疾病的方法
NZ563493A (en) 2005-05-05 2010-10-29 Fibrogen Inc Use of an anti-CTGF agent for the treatment of a vascular dysfunction in a patient
MX2008008213A (es) * 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
JP2010529947A (ja) * 2006-12-22 2010-09-02 ベラス ヘルス（インターナショナル）リミテッド 代謝性疾患および糖尿病を治療するための方法、化合物、および組成物
CA2904447C (en) * 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
NZ601660A (en) 2008-08-25 2014-05-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
PT2670411T (pt) 2011-02-02 2019-06-18 Excaliard Pharmaceuticals Inc Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
AU2014354588B2 (en) * 2013-11-28 2020-07-02 B-Creative Sweden Ab Method of treating nephropathy
WO2019032746A1 (en) 2017-08-08 2019-02-14 Fresenius Medical Care Holdings, Inc. SYSTEMS AND METHODS FOR TREATING AND ESTIMATING THE PROGRESSION OF CHRONIC RENAL DISEASE
KR20200014684A (ko) * 2018-07-31 2020-02-11 주식회사 레모넥스 Ctgf 발현 억제용 조성물
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与***生长因子特异性结合的高亲和力核酸适配体及其应用
CN109453191A (zh) * 2018-12-06 2019-03-12 郑州大学第附属医院 GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用
WO2020244540A1 (zh) * 2019-06-04 2020-12-10 江苏恒瑞医药股份有限公司 抗***生长因子抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
US6562618B1 (en) * 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
WO2000002450A1 (en) 1998-07-08 2000-01-20 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
CN1326361A (zh) * 1998-09-08 2001-12-12 亨利福特保健***公司 通过修饰、调节及抑制***生长因子来检查、预防和治疗肾脏疾病的方法
WO2000027868A2 (en) 1998-11-06 2000-05-18 Fibrogen, Inc. Connective tissue growth factor (ctgf) and methods of use
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
WO2000035936A1 (en) 1998-12-14 2000-06-22 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
ATE526041T1 (de) 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
EP2221054A1 (en) 2002-04-30 2010-08-25 Alcon, Inc. CDK inhibitors for lowering intraocular pressure
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US8258105B2 (en) 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting

Also Published As

Publication number Publication date
EP1715890A1 (en) 2006-11-02
ATE400297T1 (de) 2008-07-15
AU2005212371B2 (en) 2010-05-13
CN101884789A (zh) 2010-11-17
EP1977762A1 (en) 2008-10-08
IL177437A (en) 2013-06-27
IL177437A0 (en) 2006-12-10
DE602005008013D1 (de) 2008-08-21
US20100291098A1 (en) 2010-11-18
ES2311973T3 (es) 2009-02-16
PL1715890T3 (pl) 2009-01-30
PT1715890E (pt) 2008-10-17
US20050214294A1 (en) 2005-09-29
DK1715890T3 (da) 2008-11-17
WO2005077413A1 (en) 2005-08-25
CA2555789A1 (en) 2005-08-25
US8314059B2 (en) 2012-11-20
NZ549784A (en) 2008-06-30
EP1715890B1 (en) 2008-07-09
AU2005212371A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
HK1095762A1 (en) Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy
HK1207821A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
WO2009050506A3 (en) Combination 059
EP2006298A3 (en) Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
IL181304A0 (en) Dihydropteridinones for the treatment of cancer diseases
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
WO2006117660A3 (en) Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
SI1706112T1 (sl) Postopki za zdravljenje vnetne bolezni
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
HK1126856A1 (en) Methods for identifying polypeptide targets
WO2005118592A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006074187A3 (en) Method of treating brain cancer
GB0521716D0 (en) Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
GB0416508D0 (en) Therapeutic agents
WO2004110245A3 (en) Combination therapy for cancer treatment
GB0718878D0 (en) Photodynamic Theraphy and diagnosis
EP1768660A4 (en) COMPOUNDS AND METHODS FOR TREATING DIABETIC VASCULAR DISEASES
WO2006004774A3 (en) Laulimalide analogues as therapeutic agents
EP1788936A4 (en) CATHETER DEVICE FOR THE TREATMENT OF HERZARRHYTHMIA
IL178120A0 (en) Therapeutic combination for treatment of alzheimers disease
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
WO2005094803A3 (en) N3-pyridyl-thiamine and its use in cancer treatments